A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
← catalyst calendarNCT06968845 · readout in 406 d
Sponsored by Rein Therapeutics (industry) · RNTX — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
120estimated
Sites
36
Countries
Australia, Germany, Poland +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-02 | actual | When the study began enrolling |
| Primary completion | 2027-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Idiopathic Pulmonary Fibrosis (IPF)
Interventions
- Drug: LTI-03
- Device: Dry Powder Inhaler
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFSafety and Tolerability as measured by the incidence of treatment-emergent adverse events (TEAEs)
measured Day 1 through Week 24
Permalink · RNTX's whole pipeline · Catalyst calendar · Every registered study · What changed